Emory University's Woodruff Health Sciences Center: Baricitinib Speeds COVID-19 Recovery in NIAID Trial
December 15, 2020
December 15, 2020
ATLANTA, Georgia, Dec. 15 (TNSJou) -- Emory University's Woodruff Health Sciences Center issued the following news release:
In a randomized, controlled trial of more than 1,000 adults hospitalized with COVID-19 pneumonia, treatment with the anti-inflammatory drug baricitinib resulted in faster recovery and a greater likelihood of clinical improvement, when combined with the antiviral drug remdesivir.
The results of the international ACTT-2 (Adaptive COVID-19 Treatm . . .
In a randomized, controlled trial of more than 1,000 adults hospitalized with COVID-19 pneumonia, treatment with the anti-inflammatory drug baricitinib resulted in faster recovery and a greater likelihood of clinical improvement, when combined with the antiviral drug remdesivir.
The results of the international ACTT-2 (Adaptive COVID-19 Treatm . . .